Efficacy of ceftolozane in a murine model of Pseudomonas aeruginosa acute pneumonia: in vivo antimicrobial activity and impact on host inflammatory response

• Published in: Journal of antimicrobial chemotherapy 2013-01, Vol.68 (1), p.177-183
• Main Authors: Jacqueline, Cédric, Roquilly, Antoine, Desessard, Cyndie, Boutoille, David, Broquet, Alexis, Le Mabecque, Virginie, Amador, Gilles, Potel, Gilles, Caillon, Jocelyne, Asehnoune, Karim
• Format: Article
• Language: English
• Subjects: Acute Disease; Animal models; Animals; Anti-Infective Agents - pharmacology; Anti-Infective Agents - therapeutic use; Antibiotics; Antimicrobial activity; Antimicrobial agents; Ceftazidime; Ceftazidime - pharmacology; Ceftazidime - therapeutic use; Cephalosporins - pharmacology; Cephalosporins - therapeutic use; Colony-forming cells; Cytokines; Data processing; Disease Models, Animal; Drug resistance; Drug Resistance, Multiple, Bacterial - drug effects; Gram-negative bacteria; Homeostasis; Infection; Inflammation; Inflammation - drug therapy; Inflammation - microbiology; Inflammation - pathology; Interleukin 1; Leukocytes (neutrophilic); Lung; Macrophage inflammatory protein; Mice; Microbial Sensitivity Tests - methods; Permeability; Peroxidase; Piperacillin; Pneumonia; Pneumonia, Bacterial - drug therapy; Pneumonia, Bacterial - pathology; Pseudomonas aeruginosa; Pseudomonas aeruginosa - drug effects; Pseudomonas aeruginosa - growth & development; Pseudomonas Infections - drug therapy; Pseudomonas Infections - pathology; Survival; Tazobactam; Treatment Outcome; Tumor necrosis factor- alpha
• ISSN: 0305-7453; 1460-2091
• DOI: 10.1093/jac/dks343

To assess the activity of ceftolozane, a novel oxyimino-cephalosporin, in comparison with ceftazidime and piperacillin/tazobactam against a multidrug-resistant Pseudomonas aeruginosa strain using a murine model of pneumonia. Quantitative bacteriology, survival, histological examination, myeloperoxidase activity, proinflammatory cytokine levels in lungs and endothelial permeability were evaluated to determine the effects of ceftolozane and comparators on P. aeruginosa-induced pneumonia. After 48 h of treatment, ceftolozane reduced the bacterial load by 3-4 log(10) cfu/g of lung. Systemic dissemination of the pulmonary infection and development of lung damage were inhibited in all β-lactam-treated animals. P. aeruginosa-induced pneumonia led to elevated concentrations of tumour necrosis factor-α, interleukin (IL)-1β and macrophage inflammatory protein (MIP)-2 in the lungs. While the levels of proinflammatory cytokines decreased following ceftazidime and piperacillin/tazobactam therapy, ceftolozane exhibited increased concentrations of IL-1β and MIP-2 after 24 h of infection, resulted in significantly increased levels of recruited neutrophils within the infected lung without increasing lung endothelial permeability. These data strongly support ceftolozane as an effective option for the treatment of severe P. aeruginosa respiratory infections by improving the early pulmonary inflammatory response without impairing 48 h post-infection homeostasis.